Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Resource Utilization Analysis of Two Mobilization Regimens for Autologous Hematopoietic Cell Transplant in Multiple Myeloma
Autologous hematopoietic cell transplantation (HCT) is a standard of care therapy for multiple myeloma (MM). A key step in this procedure is the mobilization and collection of hematopoietic progenitor cells (HPC). HPC mobilization typically uses G-CSF with or without Plerixafor (P). Although P increases the effectiveness of mobilization and may reduce the number of apheresis sessions, it is associated with significantly increased cost per dose. There is significant heterogeneity to HPC collection algorithms across institutions with no clear standard. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Daniel Cancilla, Daniel Paul Nurse, Wei Wei, Christina Ferraro, Julie Coffman, Craig S Sauter, Betty K. Hamilton, Jack Khouri Tags: 224 Source Type: research

Construction and in Vitro Evaluation of a Novel Anti-CD25 Chimeric Antigen Recepto
The interleukin-2 (IL-2) receptor has been an attractive target to treat hematologic malignancies for decades, in as much as CD25 is expressed on lymphoma or leukemia cells of T- and B-cell origin, including Adult T-cell leukemia/lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma (CTCL), Hodgkin's disease, as well as B-cell non-Hodgkin's lymphoma. To date, there are no FDA approved chimeric antigen receptor T-cells (CAR-T) that treat T-cell neoplasms, so an effective CAR-T that targets a T-cell neoplasm such as Adult T-cell leukemia/lymphoma, is direly needed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ira Braunschweig Tags: 225 Source Type: research

Preclinical Development and Characterization of Humanized Anti-CD72 Nanobody Chimeric Antigen Receptor T Cells for B Cell Malignancies
Approximately 50% of patients who receive CD19 chimeric antigen receptor (CAR)-T cells relapse at one year. We previously found that CD72 is a novel immunotherapy target expressed on B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL), and that anti-CD72 nanobody CAR-T cells (CD72 nanoCARs) were highly potent. Further work revealed that humanized CD72 nanoCARs (H24 nanoCARs) unexpectedly had enhanced anti-tumor potency due to increased binding affinity for CD72. Here we further characterize H24 nanoCARs, our leading preclinical candidate, to translate this promising novel cellular therapy fr...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: William C. Temple, Adila Izgutdina, Matthew A. Nix, Benjamin J. Huang, Paul Phojanakong, Juan Antonio Camara Serrano, Fernando Salangsang, Veronica Steri, Simayijiang Xirenayi, Elliot Stieglitz, Arun P. Wiita Tags: 226 Source Type: research

Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of high-risk B-cell malignancies, but it remains associated with high rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). While prolonged toxicities are also observed in a subset of patients, to date the factors associated with the duration of CRS and ICANS are unknown. Here, we provide the first characterization of factors associated with time to CRS/ICANS resolution in patients receiving the FDA-approved CD19 CAR T-cell product axicabtagene ciloleucel (axi-cel). (Source: Biology of Blood...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Aya Albittar, Jenna M Voutsinas, Andrew J. Portuguese, Jennifer J Huang, Emily C. Liang, Natalie Wuliji, Vicky Wu, Xinyi Fan, Alexandre V Hirayama, Erik L. Kimble, Lorenzo Lovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Tags: 227 Source Type: research

T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case Series
We report 3 cases of T-cell large granular lymphocyte (T-LGL) clonal expansion involving the CAR-T population in patients (pts) with PC. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Aya Albittar, Alireza Torabi, Emily C. Liang, Andrew J. Portuguese, Jennifer J Huang, Cecilia Yeung, Erik L. Kimble, Delaney R. Kirchmeier, Aiko Torkelson, Abigail Chutnik, Ryan D. Cassaday, Aude G. Chapuis, Hans-Peter Kiem, Filippo Milano, Folashade Oteg Tags: 228 Source Type: research

Preclinical Evaluation of Chimeric Antigen Receptor-Modified Natural Killer Cells Targeting Membrane-Proximal CD33 in Acute Myelogenous Leukemia
Augmenting the cytotoxic potential of natural killer (NK) cells through the expression of a chimeric antigen receptor (CAR) promises to overcome many of the limitations of CAR-modified T cells, notably T cell-associated toxicities and difficulties with off-the-shelf allogeneic use. However, to date, the clinical efficacy of CAR-modified NK cells has been limited to CD19-expressing B cell malignancies. Toward translating this success to myeloid malignancies, we report the generation and optimization of membrane-proximal CD33-targeted CAR-modified NK cells produced by gammaretroviral transduction of peripheral blood-derived ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sanam Shahid, Theodota Kontopoulos, Jean-benoit Le luduec, Winson Cai, Sydney Souness, Sarah Yoo, Sebastien Monette, Elisa de Stanchina, Renier Brentjens, Kevin J. Curran, Katharine C. Hsu, Anthony Daniyan Tags: 229 Source Type: research

Genetic Engineering of Gamma Delta ( γδ) T Cells with the IL-2 Cytokine Receptor Orthogonal Pair (OIL-2R/OIL-2) As Immunotherapy for Pediatric Acute Myeloid Leukemia
Gamma Delta ( γδ) T cells have demonstrated potent anti-tumor activity against various cancers, including pediatric acute myeloid leukemia (AML). Previous studies in the context of αβT-cell/CD19 B-cell-depleted haploidentical hematopoietic stem cell transplantation have confirmed the cytotoxicity of γδT cel ls against AML. However, several challenges, such as their low frequency, limited in vitro expansion, restricted in vivo persistence, and IL-2-mediated expansion-related toxicities, hinder their therapeutic potential. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Wenjun Wang, Saori Takeda, Giulia Barbarito, Leon L Su, Zhenyu Yao, Alice Bertaina Tags: 230 Source Type: research

Enhanced Proliferation and Effector Function in PTPN2 Knockout CAR-T Cells Associated with Toxicities in a Non-Human Primate Model of CD20 CAR-T Cell Therapy
Relapse following CD19 CAR-T cell (CAR-T) therapy has been linked to the upregulation of negative regulators of T cell function. Recent studies showed that inhibition of the negative T cell regulator PTPN2 using a small molecule inhibitor greatly improves T cell mediated tumor clearance in murine models. We now assessed the function, proliferation, persistence and toxicity of PTPN2 KO CAR-Ts in primary human CD19 CAR-Ts and in a clinical relevant model of Non-Human Primate (NHP) CD20 CAR-Ts. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Francesca Alvarez-Calderon, Ryan Fleming, Lev Gorfinkel, Katherine A. Michaelis, James Kaminski, Xianliang Rui, Victor Tkachev, Leslie S. Kean, Ulrike Gerdemann Tags: 231 Source Type: research

CD70 CXCR2-Modified CAR T-Cells Against Acute Myeloid Leukemia
Chimeric antigen receptor (CAR) T cells have not proven as effective in acute myeloid leukemia (AML) as they have in B-cell malignancies. Reasons for therapeutic failure include lack of tumor-specific targets, antigen loss, tumor heterogeneity, suppressive leukemic microenvironment, and poor CAR T cell fitness. Our group previously developed a novel CD70 CAR T cell modified to constitutively express the IL-8 receptor, CXCR2 (8R-70CAR T cell), to treat glioblastoma (IND#23881, Huang). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: John A Ligon, Paul Castillo, Xiaojie Ma, Linchun Jin, Haipeng Tao, Duy Nguyen, Gabriel Jobin, Olga Guryanova, Jatinder K Lamba, W Greg Sawyer, Duane Mitchell, Hector Mendez-Gomez, Elias Sayour, Jianping Huang Tags: 232 Source Type: research

Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
We report here our planned interim analysis of 15 patients (pts) enrolled in a phase 2 study of anakinra to prevent CRS and ICANS after lisocabtagene maraleucel (liso-cel; NCT04359784). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Emily C. Liang, Aya Albittar, Andrew J. Portuguese, Jennifer J. Huang, Natalie Wuliji, Qian Wu, Joseph De Los Reyes, Nikki Pin, Aiko Torkelson, Delaney R. Kirchmeier, Abigail Chutnik, Barbara S. Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Mazyar Sh Tags: 233 Source Type: research

Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
Severe hematologic toxicity is a significant complication associated with CAR T-cell therapy, leading to infections, transfusion dependency, and mortality. Using data from>400 CAR T-cell patients (pts), we hypothesized a time-series clustering-based approach could: i) automate the identification of pts with impaired absolute neutrophil count (ANC) recovery, ii) enable the identification of factors associated with ANC recovery, and iii) assess predictive models of hematologic toxicity after CAR T-cell therapy. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Emily C. Liang, Aya Albittar, Andrew J. Portuguese, Jennifer J. Huang, Natalie Wuliji, Qian Wu, Joseph De Los Reyes, Nikki Pin, Aiko Torkelson, Delaney R. Kirchmeier, Abigail Chutnik, Barbara S. Pender, Joshua A. Hill, Rahul Banerjee, Andrew J. Cowan, Dam Tags: 234 Source Type: research

Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy – Are We over-Treating with Anti-Microbials?
Management of cytokine release syndrome (CRS) following CAR T cell therapy includes extensive workup to exclude infectious causes of fever. Patients are treated with broad spectrum antibiotics even with non-neutropenic fever. In key clinical trials, various range of infectious complications (grade 1-5: 18-69%; grade 3-5: 14-32%) were reported without specification regarding the day of onset. This retrospective single-centre study analyses the frequency of concurrent CRS and infectious complications during the expected CRS period. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Jana Mihalyova, Sana Ahmad, Shivani Handa, Jacques Azzi, Adriana Rossi, Shambavi Richard, Sundar Jagannath, Keren Osman, Alla Keyzner, Uroosa Ibrahim Tags: 235 Source Type: research

JAK1 Inhibition during CAR-T Cell Treatment Results in Reduction in Various Cytokines That Correlate with Cytokine Release Syndrome (CRS) and Immune Effector Cell (IEC) –Associated Neurotoxicity Syndrome (ICANS) Grades
Prophylactic treatment with itacitinib (ITA), a potent, selective oral Janus kinase (JAK)1 inhibitor, to manage onset and severity of cytokine release syndrome (CRS) and immune effector cell –associated neurotoxicity syndrome (ICANS) in response to CAR-T infusion was evaluated in the phase 2 study INCB 39110-211 (NCT04071366). The study had 2 parts: part 1 included patients treated with ITA 200 mg once daily (QD); part 2 was randomized and double-blind and evaluated ITA 200 mg twice d aily (BID) vs placebo. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Michael Pratta, Angelina Volkova, John F. DiPersio, Richard T. Maziarz, Aleksandr Lazaryan, Patricia Feldman, Cynthia Timmers, Lea Burke, Olga Ivanova, Rodica Morariu-Zamfir, Matthew J. Frigault Tags: 236 Source Type: research

CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALL
While all currently FDA approved CAR T-cells have been manufactured using bag culture, there is growing interest in closed-system bioreactors to facilitate decentralized manufacturing, improve access, and decrease cost. It is critical to understand how new platforms impact CAR T-cell functionality, yet direct comparisons between platforms are lacking. In the context of CD22 CAR T-cells for B-cell acute lymphoblastic leukemia (B-ALL), we compare clinical outcomes across two manufacturing platforms. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, Hao-Wei Wang, Bita Sahaf, Constance Yuan, Zachary Ehlinger, Sunita Patil, Kathryn Martin, Lori S Muffly, Haneen Shalabi, Kara L Davis, Matthew J. Frank, Liora Michal Schultz, Gregoire Altan-Bonnet, Crys Tags: 237 Source Type: research

Neuroimaging Findings during Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) - a CAR T Cell Neurotoxicity Imaging Virtual Archive (CARNIVAL) Study
Neuroimaging findings in immune effector cell associated neurotoxicity syndrome (ICANS) have not been systematically described. To address this gap in knowledge, we created a retrospective database (CARNIVAL) of neuroimaging studies obtained in patients with hematologic malignancies who received CAR T cell therapy (CAR T) at 6 pediatric institutions within the CARNATION consortium. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Haneen Shalabi, Jennifer McGuire, Soniya Pinto, Aashim Bhatia, Murat Alp Oztek, Ritu Shah, Arastoo Vossough, Jason Wright, Naomi Torres Carapia, Cynthia Harrison, Yasmine Kotb, Aiman Faruqi, Dickson Chen, Jacob Taylor, Kristi Lee Russell, Colleen Annesley Tags: 238 Source Type: research